StartsideSGIOY • OTCMKTS
add
Shionogi 2 ADR Representing 1 Ord Shs
Forrige sluttkurs
6,93 $
Dagsintervall
6,94 $ - 7,03 $
Årsintervall
6,22 $ - 9,11 $
Markedsverdi
1,87 bill. JPY
Gjennomsnittlig volum
233,49k
I nyhetene
Økonomi
Resultatregnskap
Omsetning
Nettoomsetning
(JPY) | sep. 2024info | Endring år til år |
---|---|---|
Omsetning | 116,38 mrd. | −4,00 % |
Driftskostnader | 52,93 mrd. | −3,66 % |
Nettoomsetning | 52,50 mrd. | 9,30 % |
Netto resultatmargin | 45,11 | 13,86 % |
Fortjeneste per aksje | — | — |
EBITDA | 53,13 mrd. | −5,14 % |
Faktisk avgiftssats | 8,28 % | — |
Balanseregnskap
Totale aktiva
Totale passiva
(JPY) | sep. 2024info | Endring år til år |
---|---|---|
Kontant / kortsiktige inv. | 303,40 mrd. | 20,22 % |
Totale aktiva | 1,46 bill. | 3,34 % |
Totale passiva | 145,93 mrd. | −18,09 % |
Total egenkapital | 1,31 bill. | — |
Utestående aksjer | 850,69 mill. | — |
P/B-forhold | 0,00 | — |
Avkastning på aktiva | 8,22 % | — |
Avkastning på kapital | 9,10 % | — |
Kontantstrøm
Netto kontantstrøm
(JPY) | sep. 2024info | Endring år til år |
---|---|---|
Nettoomsetning | 52,50 mrd. | 9,30 % |
Kontantstrøm fra drift | 45,30 mrd. | 220,14 % |
Kontanter fra investering | −17,63 mrd. | 47,30 % |
Kontanter fra finansiering | −1,11 mrd. | 94,50 % |
Netto kontantstrøm | 21,45 mrd. | 158,43 % |
Fri kontantstrøm | 8,02 mrd. | 135,46 % |
Om
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m. Wikipedia
Administrerende direktør
Grunnlagt
1878
Hovedkvarter
Nettsted
Ansatte
4 959